Application and research progress of human papillomavirus vaccine

doi:10.3760/cma.j.issn.1673422X.2018.02.012

Abstract

LIU Jing, LI Sheng-Ze. Application and research progress of human papillomavirus vaccine[J]. Journal of International Oncology, 2018, 45(2): 112-114.

［1］王凯, 王新萍, 管陈安, 等. TCT、HPVDNA及阴道镜检查在宫颈病变中的意义［J］．现代临床医学, 2015, 41(4): 276277, 279. DOI: 10.11851/j.issn.16731557.2015.04.013. ［2］ Piroozmand A, Mostafavi Zadeh SM, Madani A, et al. The association of high risk human papillomaviruses in patients with cervical cancer: an evidence based study on patients with squamous cell dysplasia or carcinoma for evaluation of 23 human papilloma virus genotypes［J］. Jundishapur J Microbiol, 2016, 9(4): e32728. DOI: 10.5812/jjm.32728. ［3］ Cerutti ML, Alonso LG, Tatti S, et al. Longlasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model［J］. Int J Cancer, 2012, 130(8): 18131820. DOI: 10.1002/ijc.26294. ［4］ Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008［J］. Sex Transm Dis, 2013, 40(3): 187193. DOI: 10.1097/OLQ.0b013e318286bb53. ［5］ Schiller JT, Castellsagué X, Garland SM, et al. A review of clinical trials of human papillomavirus prophylactic vaccines［J］. Vaccine, 2012, 30(S5)： F123F138. DOI: 10.1016/j.vaccine.2012.04.108. ［6］ de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study［J］. Lancet Oncol, 2010, 11(11): 10481056. DOI: 10.1016/S14702045(10)702308. ［7］李响, 金文婷, 满玉晶, 等. HPV疫苗预防宫颈癌的应用研究［J］. 生殖医学杂志, 2017, 26(2): 188192. DOI: 10.3969/j.issn.10043845.2017.02.018. ［8］李芹, 刘春容, 李静. 世界范围内9～26岁女性对HPV的认知现状及预防性HPV疫苗的应用现况［J］. 中国肿瘤, 2017, 26(3): 161169. DOI: 10.11735/j.issn.10040242.2017.03.A001. ［9］ Kirby T. FDA approves new upgraded Gardasil 9［J］. Lancet Oncol, 2015, 16(2): e56. DOI： 10.1016/S14702045(14)71191X. ［10］ Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introductionthe first five years［J］. Vaccine, 2012, 30 Suppl 5: F139F148. DOI: 10.1016/j.vaccine.2012.05.039. ［11］王卡娜, 郄明蓉. HPV治疗性疫苗研究现状［J］. 实用妇产科杂志, 2017, 33(2): 8991. ［12］马杰, 赵卫东. 治疗性人乳头瘤病毒疫苗研究进展［J］. 国际免疫学杂志, 2015, 38(2): 181184. DOI： 10.3760/cma.j.issn.16734394.2015.02.019. ［13］ Ma B, Maraj B, Tran NP, et al. Emerging human papillomavirus vaccines［J］. Expert Opin Emerg Drugs, 2012, 17(4): 469492. DOI: 10.1517/14728214.2012.744393. ［14］ Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7pulsed dendritic cell vaccination stage ⅠB or ⅡA cervical cancer patients: a phase Ⅰ escalatingdose trial［J］. J Virol, 2008, 82(4): 19681979. DOI: 10.1128/JVI.0234307. ［15］ Stanley M. Potential mechanisms for HPV vaccineinduced longterm protection［J］. Gynecol Oncol, 2010, 118(1 Suppl): S2S7. DOI: 10.1016/j.ygyno.2010.04.002. ［16］ Draper E, Bissett SL, HowellJones R, et al. A randomized, observerblinded immunogenicity trial of cervarix and gardasil human papillomavirus vaccines in 1215 year old girls［J］. PLoS One, 2013, 8(5): e61825. DOI: 10.1371/journal.pone.0061825. ［17］ Joura EA, Giuliano AR, Iversen OE, et al. A 9valent HPV vaccine against infection and intraepithelial neoplasia in women［J］. N Engl J Med, 2015, 372(8): 711723. DOI: 10.1056/NEJMoa1405044. ［18］ De Vincenzo R, Conte C, Ricci C, et al. Longterm efficacy and safety of human papillomavirus vaccination［J］. Int J Womens Health, 2014, 6: 9991010. DOI: 10.2147/IJWH.S50365. ［19］ Panagiotou OA, Befano BL, Gonzalez P, et al. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational followup in the Costa Rica HPV Vaccine Trial［J］. BMJ, 2015, 351: h4358. DOI: 10.1136/bmj.h4358. ［20］ Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04adjuvanted vaccine in women older than 25 years: 4year interim followup of the phase 3, doubleblind, randomised controlled VIVIANE study［J］. Lancet, 2014, 384(9961): 22132227. DOI: 10.1016/S01406736(14)60920X. ［21］ Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future CORRIGENDUM［J］. Epidemiol Infect, 2016, 144(11): 2472. DOI: 10.1017/S0950268816000777. ［22］ Macki M, Dabaja AA. Literature review of vaccinerelated adverse events reported from HPV vaccination in randomized controlled trials［J］. Basic Clin Androl, 2016, 26: 16. DOI: 10.1186/S1261001600427. ［23］ Forinash AB, Yancey AM, Pitlick JM, et al. Safety of the HPV bivalent and quadrivalent vaccines during pregnancy［J］. Ann Pharmacother, 2011, 45(2): 258262. DOI: 10.1345/aph.1P396.

[1]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[2]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[3]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[4]	Ma Xueyan, Lu Lili, Sun Pengfei. Advances in the immune microenvironment in cervical cancer [J]. Journal of International Oncology, 2023, 50(1): 47-50.
[5]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[6]	Shi Yingxia, Hu Lijun, Yu Jingping. Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 568-571.
[7]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.
[8]	Yuan Chenyang, Zhou Juying. Research progress on prognostic factors of cervical cancer [J]. Journal of International Oncology, 2022, 49(5): 307-313.
[9]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting. Screening and treatment progression of elderly cervical cancer [J]. Journal of International Oncology, 2022, 49(12): 754-758.
[10]	Ma Xiuzhen, Lu Yan, Zhao Bingbing, Qiu Hongcong, Xu Xun, Wei Min. Effects of total flavonoids from Baeckea frutescens on the migration, invasion and apoptosis of cervical cancer SiHa cells [J]. Journal of International Oncology, 2021, 48(4): 206-211.
[11]	Yu Mingyue, Chen Zhengzheng, Zhao Xuxu, Ren Pingping, Zhang Ying, Ge Li, Zhu Meiling, Zhao Weidong. Factors related to postoperative adjuvant therapy of locally advanced cervical cancer and building of a nomogram prediction model [J]. Journal of International Oncology, 2021, 48(1): 35-40.
[12]	Ding Xuchao, Cao Lili. Common active targeting nano drug delivery systems for cervical cancer [J]. Journal of International Oncology, 2021, 48(1): 61-64.
[13]	Shu Hang, Xu Zhonghua, Zhu Haochen, Yang Yahui, Lyu Yin. Research progress of radiosensitivity in cervical cancer [J]. Journal of International Oncology, 2020, 47(8): 496-500.
[14]	Zheng Xin, Chen Xiaopin. Relationship between HPV and oropharyngeal cancer in China [J]. Journal of International Oncology, 2020, 47(3): 164-168.
[15]	Song Mingze, Cheng Yiming, Li Gang, Wang Zhenming, Li Shirong. Value of P16/Ki-67 double staining detection in screening cervical cancer and precancerous lesions [J]. Journal of International Oncology, 2020, 47(11): 675-681.

Application and research progress of human papillomavirus vaccine

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments